Clinical Trials Logo

Filter by:
NCT ID: NCT06416020 Not yet recruiting - Opioid Use Disorder Clinical Trials

Integrating MOUD in African American Community Settings (Better Together)

Start date: September 1, 2024
Phase: N/A
Study type: Interventional

A multisite effectiveness-implementation study will be conducted in three sites to evaluate interventions to improve engagement and retention in MOUD with buprenorphine treatment of Black persons with OUD. The investigators hypothesize that treatment with the Better Together Integrated Collaborative Community MOUD care model (BT-MOUD) will result in better retention in treatment than standard-of-care MOUD with buprenorphine provided in the hub buprenorphine clinic only (HC-MOUD Only) through 24 weeks following randomization. BT-MOUD provides MOUD with buprenorphine in nonmedical community-based settings via telemedicine from a hub buprenorphine clinic combined with Recovery Guiding, a manual guided coaching developed for this approach, provided onsite in the community organization.

NCT ID: NCT06416007 Not yet recruiting - Cancer Clinical Trials

Lattice Radiotherapy for Dose-Escalated Palliation of Bulky Tumors

Start date: June 1, 2024
Phase: Phase 2
Study type: Interventional

The purpose of this research study is to determine if lattice radiation therapy (LRT) will provide better treatment for bulky (large) tumors than current standard of care radiotherapy.

NCT ID: NCT06415942 Not yet recruiting - Maternal Death Clinical Trials

Assessing the Maternal Outcome Monitoring Systems

MOMS
Start date: July 1, 2024
Phase: N/A
Study type: Interventional

Pregnancy-related death is a growing public health issues, which are of particular concern to minority groups, including African-Americans and Spanish-speaking Latinas. Our proposal aims to improve a patient's ability to detect warning signs of pregnancy related death and seek medical care.

NCT ID: NCT06415721 Not yet recruiting - Clinical trials for Alcohol Use Disorder

Developing Functional Connectivity-Guided TMS for Alcohol Use Disorder

Start date: July 1, 2024
Phase: N/A
Study type: Interventional

Alcohol Use Disorders are currently positioned as the third leading cause of preventable death in the United States, constituting a humanitarian crisis with substantial financial burden on society and medical facilities. While several pharmacological interventions exist, 60% of individuals who seek these treatments relapse to alcohol within 6 months. These high relapse rates are due in part to elevated brain response to alcohol cues in the environment. This study seeks to evaluate the efficacy of one session of functional Magnetic Resonance Imaging (fMRI) guided transcranial magnetic stimulation (TMS) as a strategy to reduce brain reactivity to alcohol cues.

NCT ID: NCT06415591 Not yet recruiting - Fibromyalgia Clinical Trials

Auricular Neuromodulation in Veterans With Fibromyalgia

Start date: October 1, 2024
Phase: N/A
Study type: Interventional

PENFS (percutaneous electrical nerve field stimulation) is an FDA-cleared acupuncture-like therapy applied to the external ear targeting several cranial nerve branches including the auricular branch of the vagus nerve to improve pain, physical function, and reduce symptoms of opioid withdrawal. PENFS has been previously shown to provide improvements in fibromyalgia, a difficult to treat chronic pain syndrome, which correlate with changes observed using a special kind of MRI called resting state functional connectivity MRI (rs-fcMRI) that evaluates brain activity at rest. The goals of this study are to rigorously test the initial promising results of PENFS in a much larger group of Veterans suffering from fibromyalgia and to identify potential mechanisms of PENFS effects. Further developing non-pharmacologic therapies for pain can help to improve quality of life and function for those suffering from fibromyalgia and decrease reliance on opioids and other drugs that have numerous side effects for individuals suffering from chronic pain.

NCT ID: NCT06415487 Not yet recruiting - Clinical trials for Metastatic Solid Tumor

ACE2016 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR)

Start date: May 31, 2024
Phase: Phase 1
Study type: Interventional

ACE2016 is an off-the-shelf, allogeneic gamma delta T (gdT) cell therapy derived from healthy donors, that is under investigation for the treatment of Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR). The ACE2016-001 study is an open-label, Phase I, first-in-human (FIH) study that aims to evaluate the safety and tolerability, persistency, pharmacodynamics and efficacy of ACE2016 in patients with Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR).

NCT ID: NCT06415344 Not yet recruiting - Angelman Syndrome Clinical Trials

Long-term Extension of GTX-102 in Angelman Syndrome

Start date: August 2024
Phase: Phase 3
Study type: Interventional

The primary objective of the study is to evaluate the long-term safety profile of GTX-102 in participants with Angelman Syndrome (AS)

NCT ID: NCT06414993 Not yet recruiting - Clinical trials for Polysubstance Drug Use (Indiscriminate Drug Use)

Leveraging Parents and Peers to Increase Recovery Capital in Emerging Adults

Launch
Start date: May 30, 2024
Phase: N/A
Study type: Interventional

Emerging adults (EAs; aged 18-26) are the highest-risk population for poly-substance use (misuse of more than one drug), compared to all other age groups and are the least-served population for substance use services. The overarching purpose of this pilot study is to assess whether an innovative services package, Launch, can reasonably work (is feasible) and whether providers and participants like it (acceptability). Launch works with both EAs and a supportive parent (or parental figure) and delivers peer recovery support services (PRSS) to EAs while helping parents use an effective, evidence-based program called contingency management, adapted for EAs, at home with their EA child. This study will also lay the groundwork for a future large-scale trial of Launch services.

NCT ID: NCT06414902 Not yet recruiting - Esophageal Cancer Clinical Trials

18F-AraG PET/CT as a Non-Invasive Imaging Biomarker for Chemoradiation Treatment Response in Esophageal Cancer

Start date: November 29, 2024
Phase: Early Phase 1
Study type: Interventional

To learn if 18F-FAraG PET scans can find tumors in participants with esophageal cancer and predict a participant's response to treatment.

NCT ID: NCT06414733 Not yet recruiting - Clinical trials for Metastatic Breast Cancer

Vaccine Therapy in Treating Patients With Metastatic Solid Tumors

Start date: June 2024
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of vaccine therapy in treating patients with metastatic solid tumors. Vaccines made from antibodies and peptides combined with tumor cells may help the body build an effective immune response to kill tumor cells.